Comparing GVHD Treatments: What Steroids, Targeted Medicines, Photopheresis and Cell Products Can Offer

A family comparing graft-versus-host disease treatments may receive several apparently competing recommendations. One specialist is trying to control rapidly worsening intestinal disease. Another is discussing months of treatment for chronic skin tightness. An online article offers a table of response rates without explaining who entered each study. Although all these sources use the term GVHD, they may be addressing substantially different decisions.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Before comparing two proposals, establish whether the current illness is acute GVHD, chronic GVHD or chronic disease with acute manifestations. Identify the main organs involved, current severity and previous systemic therapies. A record saying that a patient “had steroids” is insufficient. The dates, response, attempts to reduce treatment and reason for changing it can substantially alter the next discussion. Failure to respond, recurrence during tapering and inability to tolerate toxicity describe different situations.[1,2]
The ROCKstar study of belumosudil compared different dosing schedules of the same medicine. AGAVE-201 likewise evaluated different axatilimab dose groups. These studies provide important evidence about the respective treatments, but they were not direct randomized comparisons against ruxolitinib or against each other. Previous therapies, organ involvement and the period over which response was measured also differed.[6,7]
The Chinese belumosudil prescribing information revised in January 2026 covers patients aged 12 years and older with chronic GVHD inadequately responding to corticosteroids or other systemic treatment. US prior-treatment wording should not simply be copied into a Chinese eligibility statement. Chinese ruxolitinib indications should likewise be checked against domestic information, followed by confirmation of the hospital's service, supply and monitoring arrangements.[12,13]

Quick answer

Full guide

A useful comparison begins with the organ function that needs protection now. It then considers the quality of the evidence, the person's previous treatment and the practical requirements of continuing care. This guide draws on guidance, original trials and regulatory information checked through September 2026. It is a framework for discussing recommendations, rather than an individual sequence for starting or replacing medicines.

Put the same clinical facts in front of each team

Before comparing two proposals, establish whether the current illness is acute GVHD, chronic GVHD or chronic disease with acute manifestations. Identify the main organs involved, current severity and previous systemic therapies. A record saying that a patient “had steroids” is insufficient. The dates, response, attempts to reduce treatment and reason for changing it can substantially alter the next discussion. Failure to respond, recurrence during tapering and inability to tolerate toxicity describe different situations.[1,2]

Relevant constraints belong beside that history: recent infections, low blood counts, liver or kidney problems, difficulty swallowing, reduced mobility and existing vascular access. These are not administrative details. If one hospital is reviewing results obtained before a major infection and another has the latest admission report, different recommendations may reflect different information. Updating the summary is a better first step than asking the family to select whichever medicine appears most prominently online.

The comparison should also distinguish today's priority from longer-term preferences. A patient may want to return to work, but the immediate objective may be maintaining nutrition or preventing respiratory deterioration. Both goals matter; they should not be confused when assessing what a proposed treatment is expected to achieve.

Local and systemic treatments have different jobs

Treatment directed at the eyes, mouth or skin can relieve problems in those areas. Whether it is sufficient depends on the extent and severity of disease and the condition of other organs. Systemic treatment addresses broader immune-mediated injury. A person receiving systemic therapy may still need ophthalmology, oral medicine and rehabilitation. Their involvement does not, by itself, mean that the systemic drug has failed.[2,3]

Ask the team to explain which element controls active GVHD, which improves comfort or eating, and which preserves movement or other function. This separates complementary treatments from alternatives. Mouth pain alone cannot describe the condition of the lungs, while reassuring blood tests do not show whether someone can raise their arms to dress. A comparison that includes only a laboratory result can miss the outcome that most affects daily life.

There is also a distinction between suppressing ongoing inflammation and addressing damage already present. Improvement in chronic tissue restriction may follow a different course from improvement in an inflammatory rash. A mechanism described as affecting fibrosis does not establish that every established limitation will disappear. The clinical examination remains essential when setting expectations.

Acute GVHD: compare treatments at the appropriate point in care

The 2026 ASTCT guideline retains systemic corticosteroids as the first-line foundation for acute GVHD requiring systemic treatment and identifies ruxolitinib as standard second-line therapy for steroid-refractory acute GVHD. Evidence in patients whose disease has resisted steroids should not automatically be applied to every newly diagnosed patient. A newer medicine is not necessarily an appropriate replacement for the initial treatment strategy.[1]

REACH2 was a randomized phase III study comparing ruxolitinib with an investigator-selected option from a specified list in steroid-refractory acute GVHD. Its main endpoint was overall response at day 28. That design supports a comparative conclusion more strongly than an uncontrolled report of patients improving after treatment. However, overall response includes partial response and does not mean cure. The control group also represented several available approaches, rather than one identical treatment given to everyone.[4]

For a patient with worsening diarrhea, inability to maintain intake or another urgent change, the immediate decision belongs with the treating transplant service. Obtaining international opinions can support care, but waiting for a foreign quotation is not a treatment for an unstable acute complication. Stabilization and communication between teams take priority over searching for a universal winner among medicines.

Chronic GVHD: sustained control and treatment burden both matter

In chronic disease, the desired benefit may include easier movement, improved eating, fewer steroid complications and greater independence. These outcomes may change at different speeds. The team should explain which manifestations appear active and potentially responsive, which may reflect established damage, and how the proposed treatment addresses each problem. A useful plan does not promise that one intervention will normalize every organ simultaneously.[2,3]

REACH3 compared ruxolitinib with investigator-selected best available therapy in moderate or severe steroid-refractory or steroid-dependent chronic GVHD. Its three-year final report, published in 2025, supports benefit in sustained disease control. An important endpoint was failure-free survival: a composite involving events such as a new systemic GVHD treatment, death and relapse of the underlying disease. It is not an estimate of an individual's remaining lifespan or the time at which everybody can stop medication.[5]

For an individual comparison, discuss symptom change, organ stability, the possibility of a supervised steroid reduction and tolerability separately. A treatment may be attractive because it fits the patient's medical constraints or care arrangements, even when no trial proves that it is best for every person. The explanation should identify that reasoning openly.

Why response percentages do not rank belumosudil and axatilimab

The ROCKstar study of belumosudil compared different dosing schedules of the same medicine. AGAVE-201 likewise evaluated different axatilimab dose groups. These studies provide important evidence about the respective treatments, but they were not direct randomized comparisons against ruxolitinib or against each other. Previous therapies, organ involvement and the period over which response was measured also differed.[6,7]

When a website displays a response percentage, ask whether it describes response on a fixed assessment date or the best response recorded during a period of follow-up. Establish who was included in the denominator and what happened to patients who could not complete assessment. A result showing that an organ improved at one visit answers a different question from a result showing sustained control without another systemic treatment. Small differences between percentages cannot resolve those differences in study design.

The US approval for axatilimab applies to adults and pediatric patients weighing at least 40 kilograms with chronic GVHD after failure of at least two systemic lines. Those are meaningful eligibility conditions. The sources reviewed here do not establish routine Chinese availability. A US authorization page is evidence of that authorization, not confirmation that a hospital in China can supply the medicine for a particular patient.[8]

Photopheresis adds procedural and travel considerations

Extracorporeal photopheresis, or ECP, involves treating collected white blood cells outside the body with a light-sensitive medicine and ultraviolet light before returning them. It is distinct from external-beam radiotherapy and cannot be reproduced by sun exposure. Specialist guidance includes it among options for selected steroid-refractory, steroid-dependent or steroid-intolerant GVHD, while the strength of evidence varies across settings and organs.[9]

Its practical requirements differ from those of a tablet. Suitable vascular access, tolerance of the collection process, repeated attendance and a service able to continue treatment can all affect feasibility. These considerations do not establish that ECP is less effective; they determine whether the proposed course can actually be delivered. A single visit abroad should not be mistaken for a complete longitudinal treatment arrangement.

If ECP is proposed, ask how response will be assessed, what medicines will continue alongside it and what changes would trigger a different strategy. Include access care and travel demands when discussing burden. An oral medicine has its own requirements, including reliable supply, interaction review and monitoring. Comparing only the number of tablets with the number of procedures leaves out much of the work involved in either option.

Compare a cell product by its identity and indication

“Stem cell treatment” is too broad a description for a clinical comparison. NMPA information on amimestrocel injection describes conditional approval for steroid-refractory acute GVHD with predominant gastrointestinal involvement in patients aged 14 years and older. The US approval for remestemcel-L-rknd concerns a different product for pediatric steroid-refractory acute GVHD from two months of age. Their manufacturing, evidence and eligible populations are not interchangeable.[10,11]

A proposal that offers “cell repair” without naming the product, approval basis and indication is missing essential information. Nor does approval in acute intestinal GVHD demonstrate routine benefit for chronic eye, lung or skin disease. The provider should identify the patient group studied and explain how closely the current case matches it. A biological rationale alone cannot replace that evidence.

This distinction is particularly relevant when seeking care internationally. The receiving team needs to review the diagnosis and previous steroid response before discussing whether a specific product fits. Financial and travel arrangements cannot establish clinical eligibility.

Safety depends on the person's existing vulnerabilities

Infection, low blood counts and organ dysfunction may already be present before a new GVHD treatment begins. They can influence both the choice of therapy and the way it is monitored. A patient with recurrent viral reactivation poses a different problem from someone without that recent history. An event occurring after a drug starts also requires clinical assessment; timing alone does not prove that the drug caused it.[2,4,12]

The Chinese belumosudil label includes liver monitoring and clinically relevant interactions, including with proton pump inhibitors. Medicines taken for stomach symptoms can therefore matter to the main GVHD prescription. Bring a complete list, including nonprescription products, to the pharmacist. The safe response to a possible interaction is an explicit professional plan, not independently stopping or doubling medicines.[12]

When two treatments appear reasonable, ask which existing problem is most likely to limit each one. That question often produces a more useful discussion than asking which drug has “fewer side effects” overall. The answer should include the monitoring needed to detect trouble and who will act on abnormal results.

Make a China-based comparison clinically and practically complete

The Chinese belumosudil prescribing information revised in January 2026 covers patients aged 12 years and older with chronic GVHD inadequately responding to corticosteroids or other systemic treatment. US prior-treatment wording should not simply be copied into a Chinese eligibility statement. Chinese ruxolitinib indications should likewise be checked against domestic information, followed by confirmation of the hospital's service, supply and monitoring arrangements.[12,13]

Compare costs over the same period. Medicines, infusions or ECP sessions, necessary assessments, infection management and travel can contribute differently. The price of one procedure and the total for several months of medication are not equivalent estimates. No valid patient-specific RMB quotation was obtained for this guide. A hospital can be asked to provide separate initial-phase and continuation estimates, identifying which items depend on response or complications.

Before choosing between written proposals, ask each team to state its principal reason for the recommendation and the findings that would lead it to change course. The resulting explanation should connect evidence to the patient's situation. It gives the family something concrete to discuss at follow-up, beyond the name of a medicine or a claim that one approach is more advanced.

References

ASTCT. Acute GVHD treatment guideline, 2026: https://pubmed.ncbi.nlm.nih.gov/42155643/
EBMT Handbook. Chronic Graft-Versus-Host Disease, 2024: https://www.ncbi.nlm.nih.gov/books/NBK608236/
NIH. 2014 Diagnosis and Staging Working Group Report: https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
Zeiser et al. REACH2 randomized trial. NEJM, 2020: https://www.nejm.org/doi/full/10.1056/NEJMoa1917635
Zeiser et al. REACH3 three-year final analysis. JCO, 2025: https://pmc.ncbi.nlm.nih.gov/articles/PMC12316163/
Cutler et al. ROCKstar study. Blood, 2021: https://pmc.ncbi.nlm.nih.gov/articles/PMC8641099/
Wolff et al. AGAVE-201. NEJM, 2024: https://pubmed.ncbi.nlm.nih.gov/39292927/
FDA. Axatilimab approval: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease
EDF. Photopheresis guidelines, part 1, 2020: https://pmc.ncbi.nlm.nih.gov/articles/PMC7820969/
NMPA. Amimestrocel Injection: https://english.nmpa.gov.cn/2025-06/11/c_1101502.htm
FDA. Remestemcel-L-rknd approval: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric
Belumosudil Chinese prescribing information, revised January 22, 2026: https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/rezurock-cn-20260122.pdf
Novartis China. Ruxolitinib chronic GVHD indication announcement, 2024: https://www.novartis.com.cn/news/jiekewei-linsuanluketinipianzhiliaomanxingyizhiwukangsuzhubingxinshiyingzhengzaihuahuopi